Literature DB >> 23931270

Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.

Erik M Alcantar-Orozco1, Hannah Gornall, Vania Baldan, Robert E Hawkins, David E Gilham.   

Abstract

The genetic modification of peripheral blood lymphocytes using retroviral vectors to redirect T cells against tumor cells has been recently used as a means to generate large numbers of antigen-specific T cells for adoptive cell therapy protocols. However, commonly used retroviral vector-based genetic modification requires T cells to be driven into cell division; this potent mitogenic stimulus is associated with the development of an effector phenotype that may adversely impact upon the long-term engraftment potential and subsequent antitumor effects of T cells. To investigate whether the cytokines used during culture impact upon the engraftment potential of gene-modified T cells, a humanized model employing T cells engrafted with a MART-1-specific T cell receptor adoptively transferred into NOD/Shi-scid IL-2rγ(-/-) (NSG) immune-deficient mice bearing established melanoma tumors was used to compare the effects of the common γ chain cytokines IL-2, IL-7, and IL-15 upon gene-modified T cell activity. MART-1-specific T cells cultured in IL-7 and IL-15 demonstrated greater relative in vitro proliferation and viability of T cells compared with the extensively used IL-2. Moreover, the IL-15 culture prolonged the survival of animals bearing melanoma tumors after adoptive transfer. However, the combination of IL-7 and IL-15 produced T cells with improved engraftment potential compared with IL-15 alone; however, a high rate of xenogeneic graft-versus-host disease prevented the identification of a clear improvement in antitumor effect of these T cells. These results clearly demonstrate modulation of gene-modified T cell engraftment in the NSG mouse, which supports the future testing of the combination of IL-7 and IL-15 in adoptive cell therapy protocols; however, this improved engraftment is also associated with the long-term maintenance of xenoreactive T cells, which limits the ultimate usefulness of the NSG mouse model in this situation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23931270      PMCID: PMC3798231          DOI: 10.1089/hgtb.2013.022

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  45 in total

1.  IL-15 promotes the survival of naive and memory phenotype CD8+ T cells.

Authors:  Marion Berard; Katja Brandt; Silvia Bulfone-Paus; David F Tough
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

2.  T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors:  Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

3.  T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.

Authors:  Navtej Kaur; Osama S Naga; Håkan Norell; Amir A Al-Khami; Matthew J Scheffel; Nitya G Chakraborty; Christina Voelkel-Johnson; Bijay Mukherji; Shikhar Mehrotra
Journal:  Cytokine       Date:  2011-05-23       Impact factor: 3.861

4.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 5.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

6.  IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector.

Authors:  Sara Colombetti; Frédéric Lévy; Laurence Chapatte
Journal:  Blood       Date:  2009-04-21       Impact factor: 22.113

7.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

Authors:  Carolina Berger; Michael C Jensen; Peter M Lansdorp; Mike Gough; Carole Elliott; Stanley R Riddell
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

8.  Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells.

Authors:  Shicheng Yang; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

9.  IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes.

Authors:  Shin Kaneko; Sara Mastaglio; Attilio Bondanza; Maurilio Ponzoni; Francesca Sanvito; Luca Aldrighetti; Marina Radrizzani; Simona La Seta-Catamancio; Elena Provasi; Anna Mondino; Toshiro Nagasawa; Katharina Fleischhauer; Vincenzo Russo; Catia Traversari; Fabio Ciceri; Claudio Bordignon; Chiara Bonini
Journal:  Blood       Date:  2008-10-31       Impact factor: 22.113

Review 10.  Challenges in T cell receptor gene therapy.

Authors:  Benjamin J Uttenthal; Ignatius Chua; Emma C Morris; Hans J Stauss
Journal:  J Gene Med       Date:  2012-06       Impact factor: 4.565

View more
  23 in total

1.  Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Authors:  Edmund K Moon; Raghuveer Ranganathan; Evgeniy Eruslanov; Soyeon Kim; Kheng Newick; Shaun O'Brien; Albert Lo; Xiaojun Liu; Yangbing Zhao; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2015-08-31       Impact factor: 12.531

Review 2.  Humanized mice for immune checkpoint blockade in human solid tumors.

Authors:  Henry Yip; Carl Haupt; Grace Maresh; Xin Zhang; Li Li
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

Review 3.  Challenges and opportunities of allogeneic donor-derived CAR T cells.

Authors:  Yinmeng Yang; Elad Jacoby; Terry J Fry
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

Review 4.  Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.

Authors:  Marco Ruella; Saad S Kenderian
Journal:  BioDrugs       Date:  2017-12       Impact factor: 5.807

5.  Masked Chimeric Antigen Receptor for Tumor-Specific Activation.

Authors:  Xiaolu Han; Paul D Bryson; Yifan Zhao; Gunce E Cinay; Si Li; Yunfei Guo; Natnaree Siriwon; Pin Wang
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

6.  Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.

Authors:  Cesar Sommer; Bijan Boldajipour; Tracy C Kuo; Trevor Bentley; Janette Sutton; Amy Chen; Tao Geng; Holly Dong; Roman Galetto; Julien Valton; Thomas Pertel; Alexandre Juillerat; Annabelle Gariboldi; Edward Pascua; Colleen Brown; Sherman M Chin; Tao Sai; Yajin Ni; Philippe Duchateau; Julianne Smith; Arvind Rajpal; Thomas Van Blarcom; Javier Chaparro-Riggers; Barbra J Sasu
Journal:  Mol Ther       Date:  2019-04-08       Impact factor: 11.454

7.  HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.

Authors:  Sangeetha Satheesan; Haitang Li; John C Burnett; Mayumi Takahashi; Shasha Li; Shiny Xiaqin Wu; Timothy W Synold; John J Rossi; Jiehua Zhou
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 8.  Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.

Authors:  David Edward Gilham; John Anderson; John Stephen Bridgeman; Robert Edward Hawkins; Mark Adrian Exley; Hans Stauss; John Maher; Martin Pule; Andrew Kelvin Sewell; Gavin Bendle; Steven Lee; Waseem Qasim; Adrian Thrasher; Emma Morris
Journal:  Hum Gene Ther       Date:  2015-05       Impact factor: 5.695

9.  Characterization of a xenograft model for anti-CD19 CAR T cell studies.

Authors:  N Ahmadbeigi; S Alatab; M Vasei; A Ranjbar; S Aghayan; A Khorsand; K Moradzadeh; Z Darvishyan; M Jamali; S Muhammadnejad
Journal:  Clin Transl Oncol       Date:  2021-05-03       Impact factor: 3.405

Review 10.  HLA-G and humanized mouse models as a novel therapeutic approach in transplantation.

Authors:  Ashwin Ajith; Vera Portik-Dobos; Daniel D Horuzsko; Rajan Kapoor; Laura L Mulloy; Anatolij Horuzsko
Journal:  Hum Immunol       Date:  2020-02-21       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.